BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37047090)

  • 1. The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.
    Ciccone G; Ibba ML; Coppola G; Catuogno S; Esposito CL
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Oligonucleotide Aptamers for NSCLC Targeting.
    Rotoli D; Santana-Viera L; Ibba ML; Esposito CL; Catuogno S
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress on aptamer-targeted oligonucleotide therapeutics.
    Dassie JP; Giangrande PH
    Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The infinite possibilities of RNA therapeutics.
    Mollocana-Lara EC; Ni M; Agathos SN; Gonzales-Zubiate FA
    J Ind Microbiol Biotechnol; 2021 Dec; 48(9-10):. PubMed ID: 34463324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamers as targeted therapeutics: current potential and challenges.
    Zhou J; Rossi J
    Nat Rev Drug Discov; 2017 Mar; 16(3):181-202. PubMed ID: 27807347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.
    Yamakawa K; Nakano-Narusawa Y; Hashimoto N; Yokohira M; Matsuda Y
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31470511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Types of RNA therapeutics.
    Goleij P; Babamohamadi M; Rezaee A; Sanaye PM; Tabari MAK; Sadreddini S; Arefnezhad R; Motedayyen H
    Prog Mol Biol Transl Sci; 2024; 203():41-63. PubMed ID: 38360005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Progress of RNA-Based Antitumor Therapeutics.
    Fu J; Dong H; Wu J; Jin Y
    Int J Biol Sci; 2023; 19(10):3159-3183. PubMed ID: 37416764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement.
    Yan AC; Levy M
    Nucleic Acid Ther; 2018 Jun; 28(3):194-199. PubMed ID: 29883295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system.
    Wei J; Song R; Sabbagh A; Marisetty A; Shukla N; Fang D; Najem H; Ott M; Long J; Zhai L; Lesniak MS; James CD; Platanias L; Curran M; Heimberger AB
    Oncoimmunology; 2022; 11(1):2062827. PubMed ID: 35433114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Oligonucleotide Therapeutics in Oncology.
    Xiong H; Veedu RN; Diermeier SD
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.
    Zhou J; Rossi J
    J Investig Med; 2014 Oct; 62(7):914-9. PubMed ID: 25118114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.
    Bejar N; Tat TT; Kiss DL
    Curr Atheroscler Rep; 2022 May; 24(5):307-321. PubMed ID: 35364795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer.
    Takakura K; Kawamura A; Torisu Y; Koido S; Yahagi N; Saruta M
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small RNAs and non-small cell lung cancer.
    Tong AW
    Curr Mol Med; 2006 May; 6(3):339-49. PubMed ID: 16712479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.